BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Health2Sync and Novo Nordisk enhance insulin administration via digital diabetes care in Korea

July 9, 2025 | News

Users can now view their insulin injection details along with blood glucose, diet, and exercise recordings in SugarGenie





Health2Sync, Asia's leading digital chronic disease management platform, has announced the successful integration of Smart Cap Mallya® for FlexTouch® Insulin Pens data into SugarGenie, its Korean-market diabetes management app. Mallya® enables automatic recording of insulin injection details. This data can be synced directly into a patient's digital health record and shared with healthcare providers via SugarGenie, HealthSync's solution in Korea.

This innovation comes at a critical moment. Managing insulin administration records is a challenging task for both diabetes patients and healthcare professionals. In fact, a multinational survey of diabetes patients receiving insulin treatment and physicians treating diabetes patients found that 27.6% of patients experience difficulty administering insulin at the prescribed time or with meals. In the same study, 54.5% of physicians reported that their patients experience difficulty administering insulin at the prescribed time or with meals.

Mallya®, when paired with Health2Sync's connected ecosystem, significantly lowers this burden. Patients using FlexTouch® insulin pens can now have their dosage, time, and frequency data recorded and visualized in real time within the SugarGenie app.

SugarGenie's integration with Mallya® supports remote care models and automated record-keeping—an increasingly critical combination for long-term chronic condition management in South Korea. With its clean interface, real-time sync, and care team dashboard, SugarGenie is a key digital infrastructure in Korea's diabetes treatment landscape.